Logo image of BIVI

BIOVIE INC (BIVI) Stock Fundamental Analysis

NASDAQ:BIVI - Nasdaq - US09074F4054 - Common Stock - Currency: USD

1.03  0 (0%)

After market: 1.0205 -0.01 (-0.92%)

Fundamental Rating

2

Overall BIVI gets a fundamental rating of 2 out of 10. We evaluated BIVI against 561 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for BIVI as it has an excellent financial health rating, but there are worries on the profitability. BIVI does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BIVI had negative earnings in the past year.
In the past year BIVI has reported a negative cash flow from operations.
In the past 5 years BIVI always reported negative net income.
In the past 5 years BIVI always reported negative operating cash flow.
BIVI Yearly Net Income VS EBIT VS OCF VS FCFBIVI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -78.52%, BIVI is doing worse than 68.63% of the companies in the same industry.
BIVI has a Return On Equity of -88.75%. This is comparable to the rest of the industry: BIVI outperforms 48.66% of its industry peers.
Industry RankSector Rank
ROA -78.52%
ROE -88.75%
ROIC N/A
ROA(3y)-1103.91%
ROA(5y)-1006.53%
ROE(3y)-1559.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BIVI Yearly ROA, ROE, ROICBIVI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BIVI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BIVI Yearly Profit, Operating, Gross MarginsBIVI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

7

2. Health

2.1 Basic Checks

BIVI has less shares outstanding than it did 1 year ago.
BIVI has more shares outstanding than it did 5 years ago.
BIVI has a better debt/assets ratio than last year.
BIVI Yearly Shares OutstandingBIVI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
BIVI Yearly Total Debt VS Total AssetsBIVI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -17.29, we must say that BIVI is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -17.29, BIVI is doing worse than 83.78% of the companies in the same industry.
BIVI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -17.29
ROIC/WACCN/A
WACCN/A
BIVI Yearly LT Debt VS Equity VS FCFBIVI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M -30M -40M

2.3 Liquidity

BIVI has a Current Ratio of 9.31. This indicates that BIVI is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of BIVI (9.31) is better than 77.36% of its industry peers.
BIVI has a Quick Ratio of 9.31. This indicates that BIVI is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 9.31, BIVI is in the better half of the industry, outperforming 77.54% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.31
Quick Ratio 9.31
BIVI Yearly Current Assets VS Current LiabilitesBIVI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 55.40% over the past year.
EPS 1Y (TTM)55.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

BIVI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.11% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y22.85%
EPS Next 2Y30.83%
EPS Next 3Y25.16%
EPS Next 5Y23.11%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BIVI Yearly Revenue VS EstimatesBIVI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2031 20M 40M 60M 80M 100M
BIVI Yearly EPS VS EstimatesBIVI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 20 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BIVI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BIVI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BIVI Price Earnings VS Forward Price EarningsBIVI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BIVI Per share dataBIVI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

BIVI's earnings are expected to grow with 25.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.83%
EPS Next 3Y25.16%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BIVI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOVIE INC

NASDAQ:BIVI (5/23/2025, 9:15:59 PM)

After market: 1.0205 -0.01 (-0.92%)

1.03

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)09-29 2025-09-29/amc
Inst Owners5.15%
Inst Owner Change31.89%
Ins Owners0.9%
Ins Owner Change0%
Market Cap19.00M
Analysts82.5
Price Target5.61 (444.66%)
Short Float %6.67%
Short Ratio2.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-84.18%
Min EPS beat(2)-181.86%
Max EPS beat(2)13.49%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)10%
PT rev (3m)10%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.87
P/tB 0.89
EV/EBITDA N/A
EPS(TTM)-15.6
EYN/A
EPS(NY)-4.5
Fwd EYN/A
FCF(TTM)-0.94
FCFYN/A
OCF(TTM)-0.94
OCFYN/A
SpS0
BVpS1.18
TBVpS1.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -78.52%
ROE -88.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-1103.91%
ROA(5y)-1006.53%
ROE(3y)-1559.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.31
Quick Ratio 9.31
Altman-Z -17.29
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.46%
EPS Next Y22.85%
EPS Next 2Y30.83%
EPS Next 3Y25.16%
EPS Next 5Y23.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y50.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y13.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.48%
OCF growth 3YN/A
OCF growth 5YN/A